NCT00458952View on ClinicalTrials.gov

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2011

Conditions
PheochromocytomaParaganglioma
Interventions
DRUG

Ultratrace Iobenguane (MIBG) I 131

Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose

Trial Locations (3)

10021

New York Presbyterian Hospital-Weill Cornell Medical Center, New York

27710

Duke University Medical Center, Durham

02903

Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

Molecular Insight Pharmaceuticals, Inc.

INDUSTRY

NCT00458952 - Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | Biotech Hunter | Biotech Hunter